**Question:** Tuberculin test positivity indicates

A. increased immune response
B. reduced immune response
C. sensitivity to tuberculin
D. resistance to tuberculin

**Core Concept:** The tuberculin test, also known as the Mantoux test or purified protein derivative (PPD) test, is a skin test used to evaluate an individual's immune response to the tuberculin purified protein derivative. The test is a measure of T-cell activation, specifically the response to Mycobacterium tuberculosis antigens.

**Why the Correct Answer is Right:** A positive tuberculin test indicates increased immune response, as it measures the ability of the body to mount a cellular immune response against M. tuberculosis antigens. This is crucial in detecting latent tuberculosis infection (LTBI), which is a state where an individual is infected with M. tuberculosis but does not display clinical symptoms. A positive test result can indicate the presence of LTBI that may progress to active tuberculosis (TB) if the immune system fails to control the infection.

**Why Each Wrong Option is Incorrect:**

B. Reduced immune response: A negative tuberculin test result suggests a weak immune response to M. tuberculosis antigens. This is not the correct interpretation because a positive test indicates increased immune response, not reduced.

C. Sensitivity to tuberculin: This option is incorrect as the test's purpose is to evaluate immune response rather than sensitivity to tuberculin itself. A positive test indicates the body has recognized the tuberculin antigen, not its sensitivity to it.

D. Resistance to tuberculin: This option is incorrect as a positive tuberculin test demonstrates the body's ability to mount an immune response to M. tuberculosis antigens, not resistance to the tuberculin itself.

**Clinical Pearl:** The tuberculin test serves as a valuable tool in diagnosing LTBI and assessing the risk of progression to active TB disease. In high-burden TB regions, testing and following up with treatment can help control the spread of TB and prevent the development of active disease. In addition, the test can identify individuals who are eligible for preventive therapy with isoniazid, a drug that can reduce the risk of developing active TB.